NATIONAL, MULTICENTER, RANDOMISED, OPEN STUDY TO VALUATE THE EFFICACY OF DIFFERENT THERAPEUTIC STRATEGIES TO AVOID THE IMMUNOLOGIC FAILURE IN MULTIRESISTENT HIV-1 INFECTED PATIENTS.

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2004-001827-39-IT

Enrollment

Unknown

Registered

2005-06-27

Start date

2004-09-15

Completion date

Unknown

Last updated

2021-10-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV TREATMENT Level: PT Classification code 10010504

Interventions

Trade Name: VIRAMUNE*60 CPR 200 MG Product Name: NA Product Code: NA Pharmaceutical Form: Tablet INN or Proposed INN: Nevirapine CAS Number: 129618-40-2 Concentration unit: mg milligram(s) Concentrati

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Main Objective: ;Secondary Objective: ;Primary end point(s):	—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026